rs2046210 — ESR1 ESR1 rs2046210

Promoter-region variant upstream of estrogen receptor alpha (ESR1) at 6q25.1; the A allele increases ESR1 transcription and is associated with elevated endometriosis risk, endometrial cancer susceptibility, and breast cancer risk across multiple populations

See your personal result for ESR1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

ESR1 rs2046210 — When Estrogen Receptor Expression Is Turned Up

Estrogen receptor alpha (ERα), encoded by ESR1, is the master mediator of estrogen's effects on reproductive tissue. It sits in the nucleus of endometrial, breast, and uterine cells, waiting for estrogen to arrive — and when it does, it binds estrogen and turns on hundreds of downstream genes controlling cell growth, differentiation, and inflammation. Getting the amount of ERα right matters enormously: too much, and tissues become hypersensitive to estrogen, proliferating when they shouldn't.

rs2046210 sits in the promoter region11 promoter region
A promoter is a DNA region immediately upstream of a gene where transcription machinery binds to start copying the gene into RNA approximately 29 kilobases upstream of the ESR1 transcription start site, between the C6orf97/CCDC170 gene and ESR1 itself. The A allele alters the chromatin environment at this locus in a way that increases baseline ESR1 transcription — meaning cells that carry the A allele simply produce more estrogen receptor protein, making the entire estrogen-signaling axis more reactive.

The Mechanism

The variant was discovered in a genome-wide association study of Chinese women22 genome-wide association study of Chinese women
Zheng et al. Nature Genetics, 2009 and confirmed as a regulatory locus by eQTL (expression quantitative trait locus) analyses showing that risk-allele carriers have statistically higher expression of ESR1 in adjacent normal breast tissue (P = 0.04) and in the eutopic endometrium of women with endometriosis. Functional studies33 Functional studies
Sun et al. Carcinogenesis, 2016 also implicate the nearby AKAP12 gene, whose expression correlates with rs2046210 genotype in the same tissue samples (P = 0.02). The net effect is a constitutively elevated estrogen-sensing state in sensitive reproductive tissues, which predisposes to estrogen-driven proliferative conditions.

For endometriosis specifically, the mechanism is particularly direct: elevated ERα in ectopic endometrial-like lesions amplifies their response to circulating estrogen, promoting growth, survival, and inflammatory signaling in lesions implanted on peritoneal surfaces, ovaries, and pelvic ligaments. A 2024 Austrian case-control study44 A 2024 Austrian case-control study
Proestling et al. Biomedicines, 2024 found significantly increased ESR1 expression in eutopic endometrium of women with endometriosis who carried the GA genotype — confirming the mechanistic link between the rs2046210 risk allele and enhanced estrogen receptor signaling in affected tissue.

The Evidence

The breast cancer data is the most statistically robust due to sample size. The discovery GWAS by Zheng et al. (2009)55 Zheng et al. (2009)
Nature Genetics; 1,505 cases and 1,522 controls in Chinese women with two independent replication cohorts identified rs2046210 as genome-wide significant (P = 2.0 × 10⁻¹⁵). The odds ratios were 1.36 (95% CI 1.24–1.49) for heterozygotes (AG) and 1.59 (95% CI 1.40–1.82) for homozygotes (AA) compared to GG. These numbers were confirmed across >31,000 women in Chinese, Japanese, and European populations by Cai et al. (2011)66 Cai et al. (2011)
Cancer Research, and further consolidated in a meta-analysis of 235,003 subjects (13 studies)77 meta-analysis of 235,003 subjects (13 studies)
Wu et al. PLoS One, 2013 showing per-allele OR 1.13 (95% CI 1.10–1.17). A larger meta-analysis of 121,494 cases and 119,295 controls (14 studies)88 121,494 cases and 119,295 controls (14 studies)
Yang et al. Breast Cancer Research and Treatment, 2013 replicated the A allele association with OR 1.16 (95% CI 1.11–1.21).

The endometriosis evidence is more recent and from smaller studies. The 2024 Proestling et al. paper is the first to directly link rs2046210 to endometriosis risk and elevated ESR1 expression in endometrial tissue, with the GA genotype driving the association particularly in younger, leaner, and infertile women — the classic endometriosis clinical profile. The endometrial cancer association, shown in a Chinese population-based study (OR 1.28 in postmenopausal women), provides corroborating evidence that the locus broadly sensitizes estrogen-responsive gynecological tissue.

The risk conferred by a single common variant of this effect size is moderate on an individual level — an OR of 1.36 for heterozygotes means roughly 36% higher relative risk compared to GG, which, against a population endometriosis prevalence of ~10%, translates to an absolute shift of a few percentage points. It is more meaningful as a biological signal — pointing to estrogen receptor upregulation as a mechanism — than as a standalone clinical predictor.

Practical Actions

The clinical implication of elevated ESR1 expression is heightened sensitivity to estrogen. Interventions that modulate estrogen bioavailability — either by reducing exposure or supporting efficient estrogen metabolism — are especially relevant for risk-allele carriers.

For endometriosis specifically, the combination of elevated estrogen sensitivity and the high diagnostic delay (4–11 years on average) argues for proactive symptom recognition and early specialist evaluation. Risk-allele carriers who have gynecological symptoms consistent with endometriosis should request specialist evaluation rather than accept normalization of pain.

Dietary indole-3-carbinol (I3C) from cruciferous vegetables promotes 2-hydroxylation of estradiol via CYP1A1/CYP1A2, shifting metabolism toward the less proliferative 2-OH pathway and away from 16-α-OH estrone, which has been shown to reduce estrogenic proliferative signaling in endometrial and breast tissue. This is particularly relevant when ESR1 expression is constitutively elevated.

Interactions

rs12700667 (7p15.2 / HOXA10-HOXA11 locus): The 7p15.2 locus is one of the strongest replicated endometriosis GWAS signals. Carrying risk alleles at both rs2046210 (increased ESR1 expression) and rs12700667 (altered HOX gene regulation affecting endometrial development) represents two mechanistically distinct pathways converging on endometriosis susceptibility — one increasing estrogen sensitivity, the other impairing normal endometrial patterning. Women carrying risk alleles at both loci may represent a subgroup with meaningfully higher cumulative endometriosis risk. Combined recommendation: earlier gynecological evaluation, proactive fertility workup, and lower threshold for diagnostic laparoscopy. Evidence level: moderate (both loci well-replicated; interaction testing not formally published).

rs9383590 (ESR1 coding region): rs9383590 is a coding-region ESR1 variant studied alongside rs2046210 in breast cancer. Both showed independent effects on breast cancer age at onset in the Miedl et al. (2023) study, with minor homozygotes presenting years earlier than common homozygotes in ER-positive and luminal cancers. Compound effects of rs2046210 (upstream regulatory) and rs9383590 (coding/functional) on ESR1 activity have not been formally tested in endometriosis.

Genotype Interpretations

What each possible genotype means for this variant.

GG Normal ESR1 Expression Normal

No copies of the ESR1 upstream risk allele

You carry two copies of the G allele at rs2046210, the common protective genotype. About 43% of people of European ancestry share this genotype. You do not carry the A allele that is associated with elevated ESR1 expression and increased risk of estrogen-sensitive conditions including endometriosis, endometrial cancer, and breast cancer at this locus.

This does not eliminate your risk of these conditions — they are influenced by many genetic and lifestyle factors — but this particular estrogen receptor regulatory signal is not elevated for you.

AG Elevated ESR1 Expression High Risk

One copy of the ESR1 upstream risk allele — elevated estrogen receptor expression

The rs2046210 A allele acts through a regulatory mechanism — it alters the chromatin environment upstream of the ESR1 gene, increasing its baseline transcription in reproductive tissues including the endometrium and breast. Functional studies have confirmed that A allele carriers show significantly higher ESR1 mRNA levels in normal adjacent tissue (P = 0.04) and in the eutopic endometrium of women with endometriosis.

For endometriosis specifically, the 2024 Proestling et al. case-control study found the GA genotype significantly associated with endometriosis risk, with the strongest effect in younger women (under 38), lean women, and women with infertility — characteristics that overlap substantially with the typical endometriosis presentation. Elevated ESR1 in endometrial tissue creates a higher-sensitivity environment: ectopic endometrial cells that implant on peritoneal surfaces respond more robustly to circulating estrogen, leading to enhanced proliferation, lesion survival, and inflammatory signaling.

For breast cancer, the association is most pronounced for estrogen receptor-negative (ER−) tumor subtypes — somewhat counterintuitive, but consistent with elevated ESR1 expression creating complex signaling environments that may promote aggressive tumor phenotypes. The variant also shows significant association with breast cancer risk in BRCA1 mutation carriers.

The absolute risk conferred by heterozygosity is modest but clinically meaningful for gynecological surveillance planning, particularly for women with symptoms that may overlap with endometriosis.

AA High ESR1 Expression High Risk

Two copies of the ESR1 upstream risk allele — highest estrogen receptor expression at this locus

AA homozygosity at rs2046210 places you at the higher end of the genetic risk distribution for ESR1-driven estrogen sensitivity. With per-allele ORs of 1.36–1.59 for breast cancer in Asian populations and consistent directional effects in European women, this is one of the better-validated common regulatory variants for estrogen-driven conditions.

The endometriosis data specifically identifies the AA genotype as associated with disease progression in women who already have mild endometriosis (Stage I–II), suggesting that elevated ESR1 may drive lesion advancement rather than merely initiation. This is clinically relevant: it means that even mild or incidentally discovered endometriosis in someone with this genotype warrants careful monitoring for progression rather than expectant management alone.

For the breast cancer signal, AA homozygosity shows the strongest association with ER-negative tumor subtypes and with earlier age at onset, particularly in ER-positive and luminal cancers (Miedl et al. 2023). This supports an enhanced-surveillance approach rather than reassurance.

The locus also shows interaction with BRCA1 mutation status — BRCA1 carriers who also carry A alleles at rs2046210 have higher breast cancer risk than BRCA1 carriers with GG genotype. If BRCA1 or BRCA2 testing has been done or is planned, this result is relevant context.

Estrogen metabolism support (indole-3-carbinol / DIM), phytoestrogen management, and avoidance of exogenous estrogen-mimicking exposures are all relevant given the constitutively elevated ESR1 expression in sensitive tissues.